Cargando…

The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone

Background: Either sodium-glucose cotransporter-2 (SGLT-2) inhibitors or pioglitazone (Pio) has doubtful issues of bladder cancer, especially for the combination therapy with these two drugs. Our study aimed to investigate the risk of bladder cancer under combination therapy of SGLT-2 inhibitors and...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan-Rong, Liu, Chi-Hung, Sun, Wei-Chiao, Fan, Pei-Yi, Liu, Feng-Hsuan, Chen, Tien-Hsing, Wu, Victor Chien-Chia, Lin, Chihung, Hsiao, Ching-Chung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472235/
https://www.ncbi.nlm.nih.gov/pubmed/34575605
http://dx.doi.org/10.3390/jpm11090828
_version_ 1784574676850180096
author Li, Yan-Rong
Liu, Chi-Hung
Sun, Wei-Chiao
Fan, Pei-Yi
Liu, Feng-Hsuan
Chen, Tien-Hsing
Wu, Victor Chien-Chia
Lin, Chihung
Hsiao, Ching-Chung
author_facet Li, Yan-Rong
Liu, Chi-Hung
Sun, Wei-Chiao
Fan, Pei-Yi
Liu, Feng-Hsuan
Chen, Tien-Hsing
Wu, Victor Chien-Chia
Lin, Chihung
Hsiao, Ching-Chung
author_sort Li, Yan-Rong
collection PubMed
description Background: Either sodium-glucose cotransporter-2 (SGLT-2) inhibitors or pioglitazone (Pio) has doubtful issues of bladder cancer, especially for the combination therapy with these two drugs. Our study aimed to investigate the risk of bladder cancer under combination therapy of SGLT-2 inhibitors and Pio. Materials and Methods: We included 97,024 patients with type 2 diabetes mellitus (T2DM) in the Chang Gung Research Database in Taiwan from 1 January 2016 to 31 December 2019. The primary outcome was newly diagnosed bladder cancer after combination therapy with SGLT-2 inhibitors and Pio. Group 1 received both study drugs, group 2 received SGLT-2 inhibitors, group 3 received Pio, and group 4 received non-study drugs (the reference group). The secondary outcome in each group was all-cause mortality. Results: In group 1, no newly diagnosed bladder cancer was detected after a mean 2.8-year follow-up and all-cause mortality decreased significantly (adjusted hazard ratio (AHR), 0.70; 95% confidence interval (CI), 0.54–0.92) in comparison to the reference group (group 4). In group 2 and group 3, no trend of increased bladder cancer was observed (group 2: AHR 0.49, 95% CI 0.05–4.94; group 3: AHR 0.48, 95% CI 0.15–1.58) and it still reduced all-cause mortality (group 2: AHR 0.83, 95% CI 0.70–0.99; group 3: AHR 0.90, 95% CI 0.83–0.99). Conclusions: In T2DM patients without previous or active bladder cancer, the combination therapy of SGLT-2 inhibitors and Pio was not associated with newly diagnosed bladder cancer and had lower all-cause mortality.
format Online
Article
Text
id pubmed-8472235
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84722352021-09-28 The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone Li, Yan-Rong Liu, Chi-Hung Sun, Wei-Chiao Fan, Pei-Yi Liu, Feng-Hsuan Chen, Tien-Hsing Wu, Victor Chien-Chia Lin, Chihung Hsiao, Ching-Chung J Pers Med Article Background: Either sodium-glucose cotransporter-2 (SGLT-2) inhibitors or pioglitazone (Pio) has doubtful issues of bladder cancer, especially for the combination therapy with these two drugs. Our study aimed to investigate the risk of bladder cancer under combination therapy of SGLT-2 inhibitors and Pio. Materials and Methods: We included 97,024 patients with type 2 diabetes mellitus (T2DM) in the Chang Gung Research Database in Taiwan from 1 January 2016 to 31 December 2019. The primary outcome was newly diagnosed bladder cancer after combination therapy with SGLT-2 inhibitors and Pio. Group 1 received both study drugs, group 2 received SGLT-2 inhibitors, group 3 received Pio, and group 4 received non-study drugs (the reference group). The secondary outcome in each group was all-cause mortality. Results: In group 1, no newly diagnosed bladder cancer was detected after a mean 2.8-year follow-up and all-cause mortality decreased significantly (adjusted hazard ratio (AHR), 0.70; 95% confidence interval (CI), 0.54–0.92) in comparison to the reference group (group 4). In group 2 and group 3, no trend of increased bladder cancer was observed (group 2: AHR 0.49, 95% CI 0.05–4.94; group 3: AHR 0.48, 95% CI 0.15–1.58) and it still reduced all-cause mortality (group 2: AHR 0.83, 95% CI 0.70–0.99; group 3: AHR 0.90, 95% CI 0.83–0.99). Conclusions: In T2DM patients without previous or active bladder cancer, the combination therapy of SGLT-2 inhibitors and Pio was not associated with newly diagnosed bladder cancer and had lower all-cause mortality. MDPI 2021-08-24 /pmc/articles/PMC8472235/ /pubmed/34575605 http://dx.doi.org/10.3390/jpm11090828 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Li, Yan-Rong
Liu, Chi-Hung
Sun, Wei-Chiao
Fan, Pei-Yi
Liu, Feng-Hsuan
Chen, Tien-Hsing
Wu, Victor Chien-Chia
Lin, Chihung
Hsiao, Ching-Chung
The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone
title The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone
title_full The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone
title_fullStr The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone
title_full_unstemmed The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone
title_short The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone
title_sort risk of bladder cancer in type 2 diabetes mellitus with combination therapy of sglt-2 inhibitors and pioglitazone
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472235/
https://www.ncbi.nlm.nih.gov/pubmed/34575605
http://dx.doi.org/10.3390/jpm11090828
work_keys_str_mv AT liyanrong theriskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone
AT liuchihung theriskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone
AT sunweichiao theriskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone
AT fanpeiyi theriskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone
AT liufenghsuan theriskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone
AT chentienhsing theriskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone
AT wuvictorchienchia theriskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone
AT linchihung theriskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone
AT hsiaochingchung theriskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone
AT liyanrong riskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone
AT liuchihung riskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone
AT sunweichiao riskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone
AT fanpeiyi riskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone
AT liufenghsuan riskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone
AT chentienhsing riskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone
AT wuvictorchienchia riskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone
AT linchihung riskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone
AT hsiaochingchung riskofbladdercancerintype2diabetesmellituswithcombinationtherapyofsglt2inhibitorsandpioglitazone